Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
First-line chemo-free MCL combo is durable
Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.
Key clinical point: Lenalidomide/rituximab induction and maintenance is an effective outpatient regimen for mantle cell lymphoma patients.
Major finding: After 64-months of median follow-up, 21 of 33 patients with initial responses remained in remission.
Study details: Five-year follow-up of a phase 2 single-arm trial of lenalidomide/rituximab induction and maintenance in 38 patients with mantle cell lymphoma.
Disclosures: The study was supported in part by Celgene Corporation, a Clinical Translational Science Center grant, and the Lymphoma Foundation. Dr. Ruan has received research support and been a consultant for Celgene, and other coauthors reported research support and consultant relationships with the company.
Ruan J et al. Blood. 2018 Sep 4. doi : 10.1182/blood-2018-07-859769.